Request Demo
Last update 29 Aug 2025
Jiangsu Aosaikang Biomedicine Co., Ltd.
Subsidiary Company|2016|Jiangsu Sheng, China
Subsidiary Company|2016|Jiangsu Sheng, China
Last update 29 Aug 2025
Overview
Tags
Neoplasms
Digestive System Disorders
Endocrinology and Metabolic Disease
Monoclonal antibody
Fusion protein
Fc fusion protein
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20233416
评价ASKB589注射液或安慰剂联合CAPOX（奥沙利铂和卡培他滨）及PD-1抑制剂一线治疗CLDN18.2 阳性的不可切除的局部晚期、复发性或转移性胃及食管胃交界处腺癌患者的有效性和安全性的III期临床研究
[Translation] A phase III clinical study to evaluate the efficacy and safety of ASKB589 injection or placebo combined with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitors as first-line treatment for patients with CLDN18.2-positive unresectable locally advanced, recurrent or metastatic gastric and esophagogastric junction adenocarcinoma
CTR20222357
一项评价注射用ASKG315在局部晚期或转移性恶性实体瘤患者中的安全性、耐受性、人体药代动力学特征的开放、多中心的Ⅰ期临床试验
[Translation] An open, multicenter Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of ASKG315 for injection in patients with locally advanced or metastatic malignant solid tumors
NCT04632108
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with Jiangsu Aosaikang Biomedicine Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Jiangsu Aosaikang Biomedicine Co., Ltd.
Login to view more data
100 Translational Medicine associated with Jiangsu Aosaikang Biomedicine Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 14 Sep 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
2
1
Phase 3
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free